Microcap Ledger Pelthos Therapeutics Inc. $PTHS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Durham, NC
- Fiscal year end
- December 31
- Shares outstanding
- 3,828,469 [10-Q 2026-08-13]
What the company doesAI summary of filing
Pelthos Therapeutics Inc. is a biopharmaceutical company with three FDA-approved commercial products in various stages of commercialization: ZELSUVMI (berdazimer gel) for molluscum contagiosum, XEPI (ozenoxacin cream) for impetigo, and XEGLYZE (abametapir) for head lice. The company generates revenue through product sales and manufactures ZELSUVMI's active pharmaceutical ingredient at its Durham, North Carolina facility using the proprietary NITRICIL nitric oxide-based technology platform, with finished product manufacturing outsourced to third parties. The company also holds clinical-stage assets targeting the NaV1.7 sodium ion-channel for pain treatment. [10-K 2026-03-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $26.51M | −$48.49M | −$20.79M | $24.19M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $16.80M | −$43.32M | −$22.59M | $17.97M | [10-K 2026-03-19] |
| FY ended Dec 2024 | $0.00 | −$7.96M | −$5.79M | $513.0K | [10-K 2026-03-19] |
- Quarterly cash burn
- −$10.39M
- Cash runway Estimate
- ~7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 6,028,011 | [10-Q 2024-11-13] |
| 2025-03-26 | 6,103,813 | [10-K 2025-03-27] |
| 2025-05-13 | 6,595,850 | [10-Q 2025-05-13] |
| 2025-08-08 | 3,042,143 | [10-Q 2025-08-13] |
| 2025-11-07 | 3,061,681 | [10-Q 2025-11-13] |
| 2026-03-11 | 3,355,543 | [10-K 2026-03-19] |
| 2026-05-11 | 3,475,645 | [10-Q 2026-05-14] |
| 2026-08-10 | 3,828,469 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-02-02; declared effective 2026-02-09 [S-3 2026-02-02]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-02 | Greenleaf Peter | sell | 797 | $21.17 | [4 2026-10-06] |
| 2026-10-02 | Friedberg Ezra M | sell | 558 | $20.72 | [4 2026-10-06] |
| 2026-10-02 | Pauls Matthew | sell | 786 | $21.00 | [4 2026-10-06] |
| 2026-07-02 | Friedberg Ezra M | sell | 534 | $26.03 | [4 2026-07-07] |
| 2026-07-02 | Friedberg Ezra M | sell | 24 | $27.33 | [4 2026-07-07] |
| 2026-07-02 | Pauls Matthew | sell | 692 | $26.00 | [4 2026-07-07] |
| 2026-07-02 | Pauls Matthew | sell | 94 | $27.36 | [4 2026-07-07] |
| 2026-07-02 | Greenleaf Peter | sell | 712 | $26.00 | [4 2026-07-07] |
| 2026-07-02 | Greenleaf Peter | sell | 85 | $27.27 | [4 2026-07-07] |
| 2026-06-15 | Friedberg Ezra M | sell | 224 | $27.12 | [4 2026-06-17] |
| 2026-06-15 | Friedberg Ezra M | sell | 59 | $27.94 | [4 2026-06-17] |
| 2026-06-11 | Davis Todd C | buy | 35,445 | $27.80 | [4 2026-06-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-01 | 8-K | Director or officer change; Shareholder vote results |
| 2026-08-18 | DEF 14A | Proxy statement |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-13 | 10-Q/A | Amended report |
| 2026-08-13 | 8-K | Non-reliance on prior financials |
| 2026-08-07 | PRE 14A | Proxy statement |
| 2026-05-28 | 8-K | Regulation FD disclosure |
| 2026-05-21 | 8-K | Auditor change; Director or officer change |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-05-14 | 10-Q | Quarterly report |
Alerts for $PTHS
Email me when Pelthos Therapeutics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.